advertising
Dendreon's stock woes may have been unpredictable, but biotech firms often face steep odds.
Who should we look to for leadership in business and government?
From industry to the military to pleasure, Washington boat makers meet a variety of needs
Industrial developers find the welcome mat out in Frederickson as urban land becomes scarcer
Even as the economy trends downward, restauranteurs bet our hunger for red meat will grow
Cascade land conservancy's Gene Duvernoy focuses on practical solutions to preserve land
Janis Machala is founder and managing partner of Paladin Partners, an executive search and business...
As of February, the Washington economy is holding up very well compared with the national economy....
A new biotechnology company being launched out of Accelerator Corp., a business incubator in Seattle, is seeking to commercialize technology developed at Washington State University. Commercializing university research is not unusual for a start-up, except that this time, the biotech coming out of Pullman is expected to lead to cancer treatment for humans. This is a first for the landgrant university, whose traditional areas of expertise are in agricultural, veterinary and bioenergy sciences rather than human-based biomedical science. The technology is expected to yield therapies that arrest the spread of cancerous tumors. Research director for the start-up company, Recodagen, will be J. Suzanne Lindsey, the WSU researcher who first developed the technology. Recodagen has raised an undisclosed amount of initial seed funding, making it the first venture-funded start-up to come out of WSU's technology licensing program.
Print
Email